Home > Neurology > ECTRIMS 2021 > Treatment Trials and Strategies > Rituximab most effective initial MS therapy in Swedish real-world study

Rituximab most effective initial MS therapy in Swedish real-world study

Presented By
Mr Peter Alping, Karolinska Institutet, Sweden
Conference
ECTRIMS 2021
Trial
Phase 4, COMBAT-MS
Rituximab was associated with lower relapse risk and MRI lesions in treatment-naïve MS patients, compared with dimethyl fumarate, natalizumab, and injectable therapies (interferon-β, glatiramer acetate). Expanded Disability Status Scale (EDSS) score at 3 years was similar to dimethyl fumarate and natalizumab. The probability of switching therapy was lowest in rituximab users [1]. The register-based, COMBAT-MS (NCT03193866) study evaluated the effectiveness of the most frequently prescribed initial MS therapies in Sweden. MS patients ever-treated with initial rituximab (n=472), natalizumab (n=269), dimethyl fumarate (n=339), or injectables (interferon-β, glatiramer acetate; n=858), were followed between 2010 and 2020. Outcome measures were first relapse (time to event), MRI lesion rate, EDSS score, and time to treatment discontinuat...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on